Insights of Acute Lymphoblastic Leukemia with Development of Genomic Investigation.

Abstract excerpt

Treatment outcomes for acute lymphoblastic leukemia (ALL), especially pediatric ALL, have greatly improved due to the risk-adapted therapy. Combination of drug development, clinical practice, as well as basic genetic researches has brought the survival rate of ALL from less than 10% to more than 90% today, not only increasing the treatment efficacy but also limiting adverse drug reactions (ADRs). In this review,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genomics
• Share to High-Throughput Nucleotide Sequencing
• Share to Neoplasm Recurrence, Local